CD8A and melanoma: For instance, a CD8-specific scFv was developed to enable LV-mediated gene delivery to CD8+ T cells, both in vitro and in vivo, delivering melanoma-reactive T-cell receptors (TCRs) that effectively killed melanoma cells [81].